PMID- 27256431
OWN - NLM
STAT- MEDLINE
DCOM- 20170922
LR  - 20181113
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 85
IP  - 3
DP  - 2016 Sep
TI  - Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the 
      diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple 
      endocrine neoplasia type 1 patients.
PG  - 400-7
LID - 10.1111/cen.13119 [doi]
AB  - OBJECTIVE: Pancreatic neuroendocrine tumours (PNETs) are the major source of 
      disease-specific mortality in multiple endocrine neoplasia type 1 (MEN1) 
      patients. Chromogranin A (CgA), pancreatic polypeptide (PP), glucagon and gastrin 
      have some diagnostic value in sporadic PNETs, but there is very little evidence 
      for their efficacy in diagnosing PNETs in MEN1 patients. DESIGN: We performed a 
      retrospective chart review of the existing MEN1 database in our institution. 
      PATIENTS: One hundred and thirteen patients were eligible for diagnostic value 
      analysis of tumour markers. Patients were excluded if measurement of tumour 
      markers was missing, either 3 months prior to PNET diagnosis (PNET patients) or 
      prior to abdominal imaging (non-PNET patients). MEASUREMENTS: Clinicopathologic 
      characteristics and of tumour marker measurements were analysed. RESULTS: Of 293 
      confirmed MEN1 cases, 55 PNETs and 58 non-PNETs met inclusion criteria. The area 
      under the curve (AUC) for CgA, PP, glucagon and gastrin in MEN1 cases was 59.5%, 
      64.1%, 77.0% and 75.9%, respectively. The AUC for the combination of CgA, PP and 
      gastrin was 59.6%. PP, but not CgA, glucagon or gastrin was significantly 
      associated with both age and PNET functional status (P = 0.0485 and 0.0188, 
      respectively). No markers were significantly associated with sex, PNET size, 
      tumour number, tumour location, American Joint Committee on Cancer (AJCC) stage, 
      presence of lymph node metastasis, lymphovascular invasion or overall survival. 
      CgA values were not significantly lower following PNET resection than 
      pre-operatively (P = 0.554). CONCLUSIONS: The value of blood markers for 
      diagnosing PNETs in MEN1 patients is relatively low, even when used in 
      combination.
CI  - (c) 2016 John Wiley & Sons Ltd.
FAU - Qiu, Wei
AU  - Qiu W
AUID- ORCID: 0000-0003-1562-9197
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Department of Hepatobiliary Pancreatic Surgery, The First Hospital of Jilin 
      University, Changchun, Jilin, China.
FAU - Christakis, Ioannis
AU  - Christakis I
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Silva, Angelica
AU  - Silva A
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Bassett, Roland L Jr
AU  - Bassett RL Jr
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Cao, Liyun
AU  - Cao L
AD  - Department of Laboratory Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Meng, Qing H
AU  - Meng QH
AD  - Department of Laboratory Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Gardner Grubbs, Elizabeth
AU  - Gardner Grubbs E
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Zhao, Hua
AU  - Zhao H
AD  - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Yao, James C
AU  - Yao JC
AD  - Departments of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Lee, Jeffrey E
AU  - Lee JE
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Perrier, Nancy D
AU  - Perrier ND
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160630
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chromogranin A)
RN  - 0 (Gastrins)
RN  - 59763-91-6 (Pancreatic Polypeptide)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Area Under Curve
MH  - Biomarkers, Tumor/*blood
MH  - Chromogranin A/blood
MH  - Female
MH  - Gastrins/blood
MH  - Glucagon/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*pathology
MH  - Neuroendocrine Tumors/*diagnosis
MH  - Pancreatic Neoplasms/*diagnosis
MH  - Pancreatic Polypeptide/blood
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC4988913
MID - NIHMS792486
COIS- The authors declare no conflict of interest that could be perceived as 
      prejudicing the impartiality of the research reported.
EDAT- 2016/06/04 06:00
MHDA- 2017/09/25 06:00
PMCR- 2017/09/01
CRDT- 2016/06/04 06:00
PHST- 2016/03/22 00:00 [received]
PHST- 2016/05/09 00:00 [revised]
PHST- 2016/05/31 00:00 [accepted]
PHST- 2016/06/04 06:00 [entrez]
PHST- 2016/06/04 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
PHST- 2017/09/01 00:00 [pmc-release]
AID - 10.1111/cen.13119 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2016 Sep;85(3):400-7. doi: 10.1111/cen.13119. Epub 2016 
      Jun 30.